# US 2010/0168023 A1 · Injectable Botulinum Toxin Formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168023 A1
- Document ID: US20100168023A1
- Status: Published application
- Kind: A1
- Application number: 12/647,677
- Filed: 2009-12-28
- Published: 2010-07-01
- Earliest claimed: 2008-12-31
- Assignees: Revance Therapeutics, Inc.
- Inventors: Curtis L. Ruegg; Hongran F. Stone; Jacob M. Waugh
- Web page: https://patentgrep.com/patent/US20100168023A1

## CPC

- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 13/06: Anti-spasmodics
- A61P 13/10: of the bladder
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/10: Anti-acne agents
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/592: Mixtures of compounds complementing their respective functions
- A61K 2800/91: Injection
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.

## Claims

### Claim 1

A method of administering botulinum toxin to achieve a therapeutic or cosmetic effect to an individual in need thereof, the method comprising
injecting an effective amount of a composition into the individual to achieve a therapeutic or cosmetic effect,
wherein the composition comprises
a positively charged carrier comprising a positively charged backbone with a plurality of efficiency groups attached thereto,
a botulinum toxin complex, reduced botulinum toxin complex, or botulinum toxin, and
wherein the positively charged carrier is non-covalently associated with the botulinum toxin complex, reduced botulinum toxin complex, or botulinum toxin.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the botulinum toxin complex, reduced botulinum toxin complex or botulinum toxin is obtained from serotypes A, B, C, D, E, F, or G of C. botulinum.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the positively charged backbone comprises a polyamino acid.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the polyamino acid is selected from the group consisting of polylysine, polyarginine, polyhistidine, and polyornithine.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the efficiency groups comprise an amino acid sequence selected from the group consisting of (gly)n1-(arg)n2, HIV-TAT or fragments thereof, the protein transduction domain of Antennapedia, or a fragment thereof, (gly)p-RGRDDRRQRRR-(gly)q, (gly)p-YGRKKRRQRRR-(gly)q or (gly)p-RKKRRQRRR-(gly)q, and SGRQIKIWFQNRRMKWKKC;
wherein the subscript n1 is an integer from 0 to 20, the subscript n2 is independently an odd integer from about 5 to about 25, more preferably about 7 to about 17, most preferably about 7 to about 13; and
wherein the subscripts p and q are each independently integers of from 0 to 8.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the positively charged carrier stabilizes botulinum toxin against degradation.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the positively charged carrier reduces local diffusion of the botulinum toxin following injection.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the positively charged carrier has the amino acid sequence RKKRRQRRRG-(K)15-GRKKRRQRRR.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the composition has a reduced tendency to induce antibody generation following injection into the subject's body compared to BOTOX®.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the cosmetic effect is treatment of wrinkles.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the therapeutic effect is reduction of a symptom associated with a disorder selected from the group consisting of hemifacial spasm, adult onset spasmodic torticollis, anal fissure, blepharospasm, cerebral palsy, headaches, strabismus, temporomandibular joint disorder, neurologic pain, overactive bladder, rhinitis, sinusitis, acne, dystonia, dystonic contractions, hyperhidrosis, and hypersecretion of a gland controlled by the cholinergic nervous system.

### Claim 12

A method of preparing an injectable botulinum toxin formulation, the method comprising
providing an effective amount of a botulinum toxin complex, a reduced botulinum toxin complex, or a botulinum toxin;
providing a positively charged carrier comprising a positively charged backbone having a plurality of efficiency groups attached thereto;
combining the botulinum toxin complex, a reduced botulinum toxin complex, or botulinum toxin with the positively charged carrier and a pharmaceutically acceptable diluent.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the botulinum toxin complex, reduced botulinum toxin complex, or botulinum toxin is obtained from serotype A, B, C, D, E, F, or G of C. botulinum.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the positively charged backbone comprises a polyamino acid.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the polyamino acid is selected from the group consisting of polylysine, polyarginine, polyhistidine, and polyornithine.

### Claim 16 (depends on 9)

The method according to claim 9, wherein the efficiency groups are an amino acid sequence selected from the group consisting of (gly)n1-(arg)n2, HIV-TAT or fragments thereof, the protein transduction domain of Antennapedia, or a fragment thereof, (gly)p-RGRDDRRQRRR-(gly)q, (gly)p-YGRKKRRQRRR-(gly)q or (gly)p-RKKRRQRRR-(gly)q, and SGRQIKIWFQNRRMKWKKC;
wherein the subscript n1 is an integer from 0 to 20, the subscript n2 is independently an odd integer from about 5 to about 25, more preferably about 7 to about 17, most preferably about 7 to about 13; and
wherein the subscripts p and q are each independently integers of from 0 to 8.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the positively charged carrier stabilizes botulinum toxin against degradation.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the positively charged carrier reduces local diffusion of botulinum toxin following injection.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the positively charged carrier has the amino acid sequence RKKRRQRRRG-(K)15-GRKKRRQRRR.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the formulation has a reduced tendency to induce antibody generation following injection into the subject's body compared to BOTOX®.

### Claim 21

A sterile injectable composition comprising
an effective amount of a botulinum toxin complex, a reduced botulinum toxin complex, or a botulinum toxin; and
a positively charged carrier comprising a positively charged backbone having a plurality of efficiency groups attached thereto;
wherein the botulinum toxin complex, reduced botulinum toxin complex, or botulinum toxin non-covalently associates with the positively charged carrier.

### Claim 22

A syringe comprising
an effective amount of a botulinum toxin complex, a reduced botulinum toxin complex, or a botulinum toxin; and
a positively charged carrier comprising a positively charged backbone having a plurality of efficiency groups attached thereto;
wherein the botulinum toxin complex, reduced botulinum toxin complex, or botulinum toxin non-covalently associates with the positively charged carrier.

### Claim 23

A reconstituted botulinum toxin composition comprising
an effective amount of a botulinum toxin complex, a reduced botulinum toxin complex, or a botulinum toxin; and
a positively charged carrier comprising a positively charged backbone having a plurality of efficiency groups attached thereto; and
a pharmaceutically acceptable aqueous liquid diluent,
wherein the botulinum toxin complex, reduced botulinum toxin complex, or botulinum toxin non-covalently associates with the positively charged carrier,
and wherein the reconstituted botulinum toxin composition has a viscosity in the range of about 0.4 to about 2.0 cP.
